Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The treatment with SA still leaves some questions unanswered. Firstly, SA treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. Secondly, the traditional evaluation of disease activity by measuring circulating levels of GH and total IGF-I is not reliable enough

Hypotheses: Treatment of acromegaly with SA versus surgery alone is associated with:

• Glucose intolerance despite normalized insulin sensitivity

• Modified peripheral GH activity in peripheral target organs assessed on molecular endpoints

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Aarhus
• Treatments: Hormones; Somatostatin

Criteria

Inclusion Criteria:

• > 18 years

• treated acromegaly

• considered suitable

Exclusion Criteria:

• pregnancy